John Blenis
Defined the growth-signalling outputs of mTOR
PhD, Michigan State (1983) · Harvard Medical School → Weill Cornell Medicine, New York
Blenis Lab, Weill Cornell Medicine ↗
John Blenis trained at UC Berkeley and Michigan State, did postdoctoral work at Harvard, and built his career at Harvard Medical School before moving to Weill Cornell Medicine in New York. He is a pioneer of cell-signalling research.
In the early days of the field, Blenis discovered ribosomal S6 kinase (S6K) and showed that its activation depends on PI3-kinase and is blocked by rapamycin — making it the first known component of what we now call the PI3K–mTORC1 pathway. His lab helped define how this pathway is switched on through AKT, the Rheb GTPase and the TSC2 tumour suppressor, and how mTORC1 and S6K ultimately control protein synthesis and cell metabolism. He also mapped the parallel Ras–ERK–RSK pathway.
The timeline below follows Blenis's mTOR-related discoveries in this Atlas.
Milestones in the Atlas
| Year | Evidence | Study |
|---|---|---|
| 1992 | M | Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases CHU1992 Early evidence that the rapamycin–FKBP complex specifically blocks growth signalling through the p70 S6 kinases. |
| 1999 | M | Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor BRU1999 Akt phosphorylates the Forkhead transcription factor FKHRL1 (a FOXO family member), driving its cytoplasmic retention via 14-3-3 binding and blocking Fas-ligand-driven apoptosis — the discovery that placed FOXO transcription factors downstream of Akt/PI3K survival signalling. |
| 2002 | M | Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E FIN2002 Shows mammalian cell size is controlled by mTOR through its targets S6K1 and 4E-BP1/eIF4E. |
| 2003 | M | TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function SCH2003 The TOS motif mediates raptor binding and controls multisite 4E-BP1 phosphorylation by mTORC1. |
| 2005 | M | mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events HOL2005 Reveals how mTOR and S6K1 assemble the translation machinery through ordered phosphorylation. |
| 2009 | R | Molecular mechanisms of mTOR-mediated translational control MAX2009 Review of the molecular mechanisms of mTOR-mediated translational control. |
| 2011 | M | Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling YUX2011 Phosphoproteomics identify Grb10 as an mTORC1 substrate driving negative feedback on insulin/PI3K. |
| 2025 | R | mTORC1, the maestro of cell metabolism and growth HE2025 Comprehensive current review of how nutrients and growth signals are integrated by mTORC1 and the metabolic programs it commands, plus the clinical outlook for mTORC1-targeted therapy across cancer, neurodegeneration, obesity, diabetes and aging -- anchor reference for the pathway map. |
On the programme
Meetings in the Atlas calendar where John Blenis is listed among the speakers or organisers.
- past ENDO 2026 — 108th Annual Meeting of The Endocrine Society ↗ 13–16 Jun 2026 · Chicago, IL, USA · Tier 1